Bradley Pharmaceuticals Overview

  • Founded
  • 1985

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 300

Employees
  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 3

Bradley Pharmaceuticals General Information

Description

Operator of a specialty pharmaceutical company. The company markets to niche physician specialties in the U.S. and international markets. The company commercializes brands, develops new products through lifecycle management and in-licenses phase II and phase III drugs with long-term intellectual property protection. It specializes in pharmaceuticals for dermatology, podiatry, gastroenterology, women's health, respiratory and internal medicine products.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 383 Route 46 West
  • Fairfield, NJ 07004
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bradley Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bradley Pharmaceuticals‘s full profile, request access.

Request a free trial

Bradley Pharmaceuticals Patents

Bradley Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040156874-A1 Can be applied to the affected dermal site formulated as a cream, lotion, solution, gel, lacquer, ointment, foam, or any vehicle capable of applying urea directly to the affected site. Abandoned 11-Feb-2003 00000000 0
US-20040156870-A1 Administering urea to the affected area of human skin either before, after or with a topical anti-inflammatory drug. Abandoned 11-Feb-2003 000000000 00
US-20040127512-A1 Administering methscopolamine bromide for therapy of symptoms of non-constipated irritable bowel syndrome (ibs) and diarrhea-predominant ibs Abandoned 30-Dec-2002 00000000000 0
US-20040018221-A1 A mixture of urea and vitamin e for treating dry skin, dermatitis, eczema, debridement; cosmetics, skin disorders Abandoned 28-Nov-2001 0000000000 0
US-20030138466-A1 Topical products with antioxidant formulations to prevent uv-induced carcinogenesis and photoaging and to modulate desquamatory skin disorders; comprising 40 wt-% urea, 0.1-20 wt-% antioxidant, balance excipients Abandoned 28-Nov-2001 A61Q19/007 00
To view Bradley Pharmaceuticals’s complete patent history, request access »

Bradley Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Daniel Glassman President & Chief Executive Officer & Founder
Brent Lenczycki Chief Financial Officer & Vice President
To view Bradley Pharmaceuticals’s complete executive team members history, request access »

Bradley Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial